JOJean-Paul Ortonne

Jean-Paul Ortonne

*This is an algorithmically generated author record based on publicly available information.

Jean-Paul Ortonne has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ustékinumab

    by J.-P. Ortonne

  • Evidence-Based Medicine Perspective

    by Jean-Paul Ortonne, Thierry Passeron, Dj Gawkrodger, Davinder Parsad, Somesh Gupta

  • Efficacy and safety of a new single‐dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double‐blind, placebo‐controlled study

    by Jp Ortonne, Hc Korting, C Viguié‐Vallanet, C Larnier, E Savaluny

    Background  Tinea pedis is a common dermatophyte infection with frequent recurrences. Terbinafine (presently used as a 1‐week topical treatment of tinea pedis) is now available in a novel topical solution (film‐forming solution – FFS), developed to allow single application.Objectives  To demonstrate the efficacy and safety of terbinafine 1% FFS in a randomized, double‐blind, placebo‐controlled, phase III trial, and to determine relapse or re‐infection rate of tinea pedis at 12 weeks.Patients/methods  Fifty‐four centres (27 in France; 27 in Germany) enrolled 273 evaluable patients (2 : 1 randomization). Patients applied terbinafine 1% FFS or placebo only once between, under and over the toes, soles and sides of both feet. Efficacy assessments included direct microscopy, mycological culture, and clinical signs and symptoms at baseline, and at weeks 1, 6 and 12 after the single drug application.Results  Effective treatment (negative mycology plus absent/minimal symptoms) at week 6 in the terbinafine 1% FFS group was 63%; vehicle was 17% (P 0.0001). Mycological cure was 72% in the terbinafine group and 21% in the placebo (P 0.0001) at week 6. Clinical signs/symptoms decreased significantly in the active group compared to the placebo. The self‐assessment of itching and burning sensation by the patient showed a clear reduction in symptoms starting 15 min after treatment application (this could be attributed to the cooling effect of the FFS). Recurrence (positive culture at 3 months) occurred in 12.5% of the effectively treated patients at week 6 in the terbinafine group. FFS was well tolerated.Conclusion  Terbinafine 1% FFS, single dose application is an effective, safe and convenient treatment for tinea pedis. The relapse/re‐infection rate 3 months after the end of single‐dose therapy is similar to that previously demonstrated in a study using terbinafine 1% cream for 7 days.


  • An open‐label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis

    by Jp Ortonne, A Khemis, Jym Koo, J Choi

    Background  Alefacept, a fully human LFA‐3/IgG1 fusion protein, is a selective biological agent approved in the United States for the treatment of chronic plaque psoriasis. In phase 3 trials, clinical improvement and prolonged off‐treatment remission of psoriasis correlated with reductions in circulating memory T cells. Reductions in pathogenic epidermal T cells in psoriatic lesions also have been noted following phototherapy with ultraviolet B (UVB) light. Because alefacept and UVB target T cells in different ways, combination therapy with these two agents may lead to greater efficacy.Objectives  To determine the safety, tolerability, and efficacy trends of combination therapy with alefacept plus UVB light in patients with chronic plaque psoriasis.Methods  In an open‐label, parallel‐group study conducted at two sites, one in France and one in the United States, patients with chronic plaque psoriasis who were candidates for phototherapy received 12‐weekly intramuscular injections of alefacept, 15 mg. In addition, patients were randomized to one of three treatment arms: no UVB treatment, 6‐week UVB treatment, and 12‐week UVB treatment. UVB treatment consisted of narrowband (NB) UVB at the site in France and broadband (BB) UVB at the site in the United States. The 12‐week treatment period was followed by a 12‐week follow‐up period. Clinic visits occurred weekly during treatment and every 2–4 weeks during follow‐up.Results  A total of 60 patients (n = 30/site) were enrolled in the study. Alefacept was well tolerated when administered in combination with UVB treatment and as monotherapy. There was no evidence of increased phototoxicity or photosensitivity with the combination. At each study site, alefacept/UVB provided a higher overall response rate and led to a more rapid onset of response compared with alefacept monotherapy. Of patients who achieved ≥ 50% reduction from baseline Psoriasis Area Severity Index (PASI 50) at 2 weeks after the last dose of alefacept, 75–100% in the combination therapy groups maintained this response throughout follow‐up in the absence of further psoriasis therapy.Conclusions  In patients with chronic plaque psoriasis, combination therapy with alefacept plus short‐term (6–12 weeks) UVB treatment is well tolerated with a trend toward greater and more rapid efficacy than alefacept alone.


  • Efficacy of Treatment with Calcipotriol/Betamethasone Dipropionate Followed by Calcipotriol Alone Compared with Tacalcitol for the Treatment of Psoriasis vulgaris: A Randomised, Double-Blind Trial

    by J.-P. Ortonne, R. Kaufmann, M. Lecha, M. Goodfield

    Background: A two-compound product containing calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g (Daivobet®, Dovobet®) has been demonstrated to be an effective, once daily, treatment for psoriasis vulgaris. Objective: To compare the efficacy and safety of treatment with the two-compound product for 4 weeks followed by calcipotriol for 4 weeks, with that of tacalcitol for 8 weeks in patients with stable psoriasis vulgaris. Methods: 501 patients were randomised to double-blind treatment with the two-compound product followed by calcipotriol 50 µg/g once daily, or to tacalcitol 4 µg/g once daily. Results: Treatment with the two-compound product/calcipotriol was significantly more effective than tacalcitol in terms of mean percentage PASI reduction (65.0 vs. 33.3% at week 4 and 59.0 vs. 38.4% at week 8; p < 0.001 for both). Conclusion: A treatment regimen comprising calcipotriol/betamethasone ointment (Daivobet) for 4 weeks followed by calcipotriol for 4 weeks is superior to tacalcitol ointment for 8 weeks in patients with psoriasis vulgaris.


    • 18 February 2004
      • Vol. 3  (1) , 13-20

    Redefining clinical response in psoriasis: targeting the pathological basis of disease.

    by Jean-Paul Ortonne

    Psoriasis is a chronic inflammatory disease of the skin that can have a major effect on patient quality of life. Conventional psoriasis treatments, often identified empirically, fail to meet the clinical needs for a safe and remittive therapy. These unmet needs, together with the rapid advances in understanding the molecular basis of psoriasis, have led to the development of targeted biologic therapies. Using recombinant DNA technology, a new generation of therapeutic agents is being designed to interfere at specific pathogenic steps that involve T-cells or T-cell-mediated immune responses. These targeted therapies promise improved tolerability and safety in the treatment of psoriasis. Furthermore, they will redefine clinical response in psoriasis by providing long-lasting remissions of disease and extended treatment-free periods.


    • 18 February 2004
      • Vol. 14  (1) , 41-5

    Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.

    by Jean-Paul Ortonne, Jörg C Prinz

    Psoriasis is a chronic immune-mediated disease affecting the skin and sometimes the joints. Approximately 14 million people in Europe have psoriasis and the disease has a profound effect on the quality of life of patients worldwide. Currently available therapies for psoriasis have several shortcomings, including organ-based toxicity, generalized immunosuppression, short duration of response, and inconvenient regimens. Alefacept is a recombinant, fully human fusion protein that selectively targets the memory T cell population implicated in psoriasis pathogenesis. Alefacept is unique among psoriasis treatments because of its selective therapeutic action, ability to induce lengthy disease remissions even in the absence of continued therapy, positive effect on quality of life, and favorable safety profile. Two courses of alefacept confer greater efficacy and duration of clinical improvement versus that observed with a single course. This novel biologic agent is currently approved in the United States and under regulatory review in Europe for moderate to severe chronic plaque psoriasis.


    • 16 April 2003
      • Vol. 13  (2) , 117-23

    Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.

    by Jean-Paul Ortonne, Mark Lebwohl, Christopher Em Griffiths

    This international, double-blind study examined the effects of alefacept on circulating lymphocytes in 507 patients with chronic plaque psoriasis, and determined whether these effects were related to clinical improvement. Patients were randomized to intramuscular placebo, alefacept 10 mg, or alefacept 15 mg once weekly for 12 weeks followed by 12 weeks of observation. Alefacept dose-dependently reduced CD4+ and CD8+ memory T cells, while sparing the na ve population. The greatest reductions in disease activity occurred in patients with the largest decreases in memory T cells. For example, a 50 % reduction from baseline Psoriasis Area Severity Index at any time during treatment or follow-up was observed in 66 % of patients who had the greatest reductions in CD4+ memory T cells versus in 40 % of patients who had the smallest reductions in this T-cell subset. These results provide further support for the deleterious roles of CD4+ and CD8+ memory T-cell subpopulations in psoriasis pathogenesis.